Carregant...
Dpp4 inhibition as a therapeutic strategy in cardiometabolic disease: Incretin-dependent and -independent function
Cardiometabolic disorders including obesity, diabetes and cardiovascular disease are among the most severe health problems worldwide. DPP4 enzymatic inhibitors were first developed as anti-diabetic reagents which preserve incretin hormones and promote post-prandial insulin secretion. It's been...
Guardat en:
| Publicat a: | Int J Cardiol |
|---|---|
| Autors principals: | , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Elsevier Ireland Ltd.
2015
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7114201/ https://ncbi.nlm.nih.gov/pubmed/26142202 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ijcard.2015.06.076 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|